Severe lithium-induced nephrogenic diabetes insipidus: The diuresis paradox
DOI:
https://doi.org/10.7196/SAMJ.2025.v115i3.2651Keywords:
nephrogenic diabetes insipidus, arginine vasopressin resistance, lithium, hypothyroidism, lithium-induced, lithium toxicityAbstract
We report a case of profound nephrogenic diabetes insipidus (NDI) in which renal resistance to antidiuretic hormone results in dilute polyuria despite normal circulating concentrations. A 28-year-old man with bipolar mood disorder presented to his local clinic with symptoms suggestive of lithium toxicity. Plasma lithium concentrations and thyroid-stimulating hormone (TSH) were taken, but results were not acted upon. One week later, he presented obtunded, severely dehydrated and in renal failure. His plasma lithium concentration was 4.3 mmol/L (toxic threshold >1.5 mmol/L) and TSH >100 mIU/L. After admission to the intensive care unit, including haemodialysis and 12 days of ventilation, he developed profound polyuria, with a peak output of 15 L/day. Amiloride with hydrochlorothiazide adequately reduced the polyuria. Management of lithium-induced NDI remains complex, and includes diuretics, which paradoxically reduce polyuria in this setting. Failure to follow up critical results led to profound morbidity, and is a crucial learning point in this case.
References
1. Angelousi A, Alexandraki KI, Mytareli C, Grossman AB, Kaltsas G. New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance). J Neuroendocrinol 2023;35(1):e13233. https://doi.org/10.1111/jne.13233
2. Gubbi S, Hannah-Shmouni F, Koch CA, Verbalis JG, et al. Diagnostic testing for diabetes insipidus. Endotext, 2022. https://pubmed.ncbi.nlm.nih.gov/30779536/ (accessed 10 March 2025).
3. Cuzzo B, Padala SA, Lappin SL. Physiology, vasopressin. StatPearls, 2024. https://www.ncbi.nlm.nih. gov/books/NBK538334/ (accessed 7 March 2025).
4. Hui C, Khan M, Khan Suheb MZ, Radbel JM. Arginine vasopressin disorder (diabetes insipidus). StatPearls, 2024. https://www.ncbi.nlm.nih.gov/books/NBK538168/ (accessed 7 March 2025).
26 April 2025, Vol. 15, No. 3
IN PRACTICE
5. Hilal-Dandan R, Knollmann B, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw Hill Education, 2018.
6. De Groot T, Alsady M, Jaklofsky M, et al. Lithium causes G2 arrest of renal principal cells. J Am Soc Nephrol 2014;25(3):501-510. https://doi.org/10.1681/ASN.2013040411
7. Ott M, Forssén B, Werneke U. Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: A retrospective cohort study. Ther Adv Psychopharmacol 2019;9:2045125319836563. https://doi.org/10.1177/2045125319836563
8. Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: A literature review of approaches to clinical management and risk stratification. BMC Nephrol 2018;19(1):305. https://doi.org/10.1186/s12882- 018-1101-4
9. Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 2015;11(10):576-588. https://doi.org/10.1038/nrneph.2015.89
10. Jose CJ, Perez-Cruet J. Incidence and morbidity of self-induced water intoxication in state mental hospital patients. Am J Psychiatry 1979;136(2):221-222.
11. Li JJ, Tan S, Kawashita T, Tagle CA, Farmand F. Central diabetes insipidus in the background of lithium use: Consider central causes despite nephrogenic as the most common. Am J Case Rep 2023;24:e939034. https://doi.org/10.12659/AJCR.939034
12. Shnaider A, Azab AN. Lithium-induced nephrogenic diabetes insipidus – a case report and discussion on the pathophysiological mechanism. Int J Nephrol Kidney Failure 2015;1(3):21719030. http://doi. org/10.16966/2380-5498.113
13. Christensen BM, Zuber AM, Loffing J, et al. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus. J Am Soc Nephrol 2011;22(2):253-261. http://doi.org/10.1681/ ASN.2010070734
14. Ljubicic D, Letica-Crepulja M, Vitezic D, Bistrovic IL, Ljubicic R. Lithium treatments: Single and multiple daily dosing. Can J Psychiatr 2008;53(5):323-331. http://doi.org/10.1177/070674370805300507
15. Rao R, Patel S, Hao C, Woodgett J, Harris R. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol 2010;21(3):428-437. http://doi.org/10.1681/
ASN.2009060672
16. Akbari P, Khorasani-Zadeh A. Thiazide diuretics. StatPearls, 2024 https://www.ncbi.nlm.nih.gov/ books/NBK470409/ (accessed 7 March 2025).
17. Danilo C. Use of amiloride in lithium-induced nephrogenic diabetes insipidus. J Anal Pharm Res 2018;7(3):286-287. http://doi.org/10.15406/japlr.2018.07.00257
18. Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydro- chlorothiazide to patients with vasopressin-resistant diabetes insipidus. J Clin Invest 1962;41(11):1988- 1997. http://doi.org/10.1172/JCI104668.
19. Knoers N, Monnens LAH. Nephrogenic diabetes insipidus: Clinical symptoms, pathogenesis, genetics and treatment. Pediatric Nephrol 1992;6(5):476-482. http://doi.org/10.1007/BF00866321
20. De Groot T, Doornebal J, Christensen BM, et al. Lithium-induced NDI: Acetazolamide reduces polyuria but does not improve urine concentrating ability. Am J Physiol Renal Physiol 2017;313(3):F669-F676. https://doi.org/10.1152/ajprenal.00149.2017
21. Kortenoeven ML, Li Y, Shaw S, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 2009;76(1):44-53. https:// doi.org/10.1038/ki.2009.97
22. Gordon CE, Vantzelfde S, Francis JM. Acetazolamide in lithium-induced nephrogenic diabetes insipidus. N Engl J Med 2016;375(20):2008-2009. https://doi.org/10.1056/NEJMc1609483
23. Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 1986;108(2):305-311. https://doi.org/10.1016/S0022-3476(86)81010-1
24. Gilson L, Elloker S, Olckers P, Lehmann U. Advancing the application of systems thinking in health: South African examples of a leadership of sensemaking for primary health care. Health Research Policy and Systems 2014;12(1):30. https://doi.org/10.1186/1478-4505-12-30
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Gayle Tatz, Prof IL Ross, JA Dave, M Blockman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
